Department of Cardiology, National University of Ireland, Galway (NUIG) and CORRIB Corelab and Center for Research and Imaging, Galway, Ireland.
EuroIntervention. 2021 Dec 17;17(12):e1009-e1018. doi: 10.4244/EIJ-D-21-00386.
The Xeltis biorestorative transcatheter heart valve (BTHV) leaflets are made from an electrospun bioabsorbable supramolecular polycarbonate-urethane and are mounted on a self-expanding nitinol frame. The acute haemodynamic performance of this BTHV was favourable.
We sought to demonstrate the preclinical feasibility of a novel BTHV by evaluating the haemodynamic performances of five pilot valve designs up to 12 months in a chronic ovine model.
Five design iterations (A, B, B', C, and D) of the BTHV were transapically implanted in 46 sheep; chronic data were available in 39 animals. Assessments were performed at implantation, 3, 6, and 12 months including quantitative aortography, echocardiography, and histology.
At 12 months, greater than or equal to moderate AR on echocardiography was seen in 0%, 100%, 33.3%, 100%, and 0% in the iterations A, B, B', C, and D, respectively. Furthermore, transprosthetic mean gradients on echocardiography were 10.0±2.8 mmHg, 19.0±1.0 mmHg, 8.0±1.7 mmHg, 26.8±2.4 mmHg, and 11.2±4.1 mmHg, and effective orifice area was 0.7±0.3 cm2, 1.1±0.3 cm2, 1.5±1.0 cm2, 1.5±0.6 cm2, and 1.0±0.4 cm2 in the iterations A, B, B', C, and D, respectively. On pathological evaluation, the iteration D demonstrated generally intact leaflets and advanced tissue coverage, while different degrees of structural deterioration were observed in the other design iterations.
Several leaflet material iterations were compared for the potential to demonstrate endogenous tissue restoration in an aortic valve in vivo. The most promising iteration showed intact leaflets and acceptable haemodynamic performance at 12 months, illustrating the potential of the BTHV.
Xeltis 生物修复经导管心脏瓣膜(BTHV)的瓣叶由电纺生物可吸收超分子聚碳酸酯-聚氨酯制成,并安装在自扩张镍钛诺框架上。该 BTHV 的急性血液动力学性能良好。
我们通过在慢性绵羊模型中评估五个试验瓣膜设计的血液动力学性能,旨在证明新型 BTHV 的临床前可行性,时间长达 12 个月。
将五个 BTHV 设计迭代(A、B、B'、C 和 D)经心尖植入 46 只绵羊;39 只动物有慢性数据。评估在植入时、3 个月、6 个月和 12 个月进行,包括定量主动脉造影、超声心动图和组织学检查。
在 12 个月时,迭代 A、B、B'、C 和 D 的超声心动图上大于或等于中度 AR 的比例分别为 0%、100%、33.3%、100%和 0%。此外,超声心动图上跨瓣平均梯度分别为 10.0±2.8mmHg、19.0±1.0mmHg、8.0±1.7mmHg、26.8±2.4mmHg 和 11.2±4.1mmHg,有效瓣口面积分别为 0.7±0.3cm2、1.1±0.3cm2、1.5±1.0cm2、1.5±0.6cm2 和 1.0±0.4cm2。在病理评估中,迭代 D 显示瓣叶一般完整,组织覆盖先进,而其他设计迭代则观察到不同程度的结构恶化。
为了在体内主动脉瓣中证明内源性组织修复的潜力,比较了几种瓣叶材料迭代。最有前途的迭代在 12 个月时显示出完整的瓣叶和可接受的血液动力学性能,说明了 BTHV 的潜力。